Markets | | | AT&T’s yield was attractive before the epidemic struck because it was relatively high from several perspectives. Now that the market has entered bear-market territory the stock is paying an eye-popping 7.25% Read the Full Story |
|
From Our PartnersSimple Options Trading for Beginners retails on Amazon for $19.95 and has 4 out of 5 stars. It was written by a stock market trading veteran with over 44 years of experience. Because of a special promotion, this book is 100% FREE for you today. | | So get it here now... |
|
Stocks | | | A Vee-Shaped Recovery? I Don’t Think So
As dark as the days may seem, a rebound is brewing in the stock market (SPY). The combination of this selloff’s suddenness and depth has left it ripe for such a move. The question is how high the rebound will go and then what comes next? With earn... Read the Full Story |
|
Stocks | | | As many on Wall Street scramble to simply survive market crashes, like the one we’ve seen in recent weeks, and to come out as unscathed as possible, others keep one eye open for opportunities that only come about as a result of such crashes. One of the most well known and most-watched for of t... Read the Full Story |
|
From Our PartnersToday, we are inviting you to take a free peek at our proprietary, exclusive and up-to-the-minute list of [link]20 stocks that Wall Street's top analysts think won't survive the current crisis[/link].
These are true "Strong Sell" stocks.
Many of these appear to have good fundamentals and might seem like okay investments as recently as a week ago, but something is wrong. Analysts smell something seriously rotten about these companies.
Sell-side analysts may not have a 100% hit rate on their buy ratings, but they almost always are spot on when they throw red flags and issue "sell" ratings.
If any of these stocks are lurking around in your portfolio, you may seriously want to consider dumping them before COVID-19 gets much worse. | | Click Here to View the Stocks |
|
Stocks | | |
It's been a terrible month for retail. Retail that isn't grocery stores or pharmacies, that is; that retail is doing pretty nicely. But if you're not selling food, medicine, or toilet paper, you're having a pretty terrible month. Assuming you're even open to begin with, dismissed as “nonesse... Read the Full Story |
|
Markets | | |
If you were to make a list of things you didn't expect to see this morning, it might look a little mundane, featuring things like “toilet paper available for sale” or “an open shopping mall.” If you were looking for an upgrade to Boeing (NYSE: BA) stock, then you may want t... Read the Full Story |
|
From Our PartnersThis hidden income strategy was just leaked and it can be yours now. It goes in depth about how you can start off with a small account and turn that into your own weekly paycheck. Learn how you can GAIN that extra advantage over what others aren't doing. | | Click here to get this secret |
|
The Early Bird Stock Of The Day NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida. | | View Today's Stock Pick |
|
